FDA Grants Approval for Another Generic Abortion Pill

U.S. federal authorities have authorized a new generic version of the abortion medication mifepristone, causing swift opposition from anti-abortion groups and political figures aligned with former President Trump.

Evita Solutions recently shared that the FDA has sanctioned their cost-effective version of the pill, which is eligible for use up to the tenth week of pregnancy. This company becomes the second to receive approval for a generic version following another pharmaceutical manufacturer.

The decision drew quick criticism from conservative circles.

Missouri Senator Josh Hawley, a Republican, voiced his discontent on X, saying he no longer trusts the FDA's leadership.

In an interview with CBS News, Kristan Hawkins, president of Students for Life of America, declared that arguing the FDA’s hands are tied ignores reality. She labeled the drugs hazardous and condemned the administration.

Marjorie Dannenfelser, leader of Susan B. Anthony Pro-Life America, labeled the FDA's decision as excessively reckless.

This criticism emerges as key health figures under President Trump, including Health Secretary Robert F. Kennedy Jr., are under amplified pressure from anti-abortion advocates to reassess mifepristone, which has maintained its approval since 25 years ago with consistent safety affirmations by the FDA.

HHS spokesperson Andrew Nixon emphasized to CBS News that introducing generic drugs is largely beyond the agency's discretion, noting that federal law mandates the approval of new generic applications that match brand-name drugs.

Kennedy, alongside FDA Commissioner Dr. Marty Makary, promised an in-depth safety evaluation of the drug.

In a letter, Kennedy and Makary stated, "The department is actively reviewing all evidence regarding the drug's safety and efficacy through real-world outcomes."

Dr. Celine Gounder from CBS News suggested that while it is unlikely the FDA will revoke approval, potential safety adjustments might limit access, such as constraints on telehealth or mailing prescriptions.

During his campaign, Mr. Trump communicated to CBS News' Caitlin Huey-Burns his position.

Back in 2021, under President Joe Biden, the FDA expanded the drug’s availability through online prescriptions and mail services, a change opposed by anti-abortion groups.

Typically, FDA processes for generic drugs are routine, with equivalents approved post-patent expiry. Generic producers generally just need to confirm their product's formulation matches the original.

The FDA often wraps up such applications in ten months. Evita Solutions, however, submitted their request four years ago, according to public FDA filings.

Evita Solutions didn't provide comments when reached out by the Associated Press.

On its web platform, Evita asserts its belief in universal, safe, affordable abortion access.

An additional generic version isn't anticipated to revolutionize access, as mifepristone is generally partnered with misoprostol for medical abortions. Many women opt for medication abortions, where mifepristone halts progesterone while misoprostol prompts uterine contractions.

Reproductive Freedom for All's CEO, Mini Timmaraju, regards the FDA's decision as standard procedure, highlighting that it's odd for a routine approval to draw political fire, largely due to some conservative politicians turning healthcare into a battleground.

In numerous states, laws limit mifepristone availability, either outright banning abortion or introducing particular drug restrictions. These constraints face numerous legal challenges in the courts.

Many leading medical associations, like the American Medical Association, don't support such restrictions on the medication.

Ongoing Abortion Controversies

Content from 2025 CBS Interactive Inc. All rights reserved. Redistribution, publication, or broadcast is restricted. Report contributions from the Associated Press included.